<DOC>
	<DOCNO>NCT03098589</DOCNO>
	<brief_summary>To understand safety efficacy Revlimid® Capsules 2.5 mg 5 mg ( hereinafter refer Revlimid ) actual condition use patient relapse refractory adult T-cell leukemia lymphoma ( hereinafter refer relapsed refractory Adult T-cell Leukemia Lymphoma ( ATLL ) ) . 1 . Planned registration period 3 year 2 . Planned surveillance period 4 year 6 month month approval partial change approve item grant relapsed refractory ATLL</brief_summary>
	<brief_title>Revlimid® Capsules Drug Use-results Surveillance ( Relapsed Refractory ATLL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Relapsed Refractory Adult Tcell Leukemia Lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Adult T-cell Leukemia Lymphoma</keyword>
	<keyword>Teratogenicity</keyword>
	<keyword>Myelosuppression</keyword>
	<keyword>Haemorrhage</keyword>
	<keyword>Infection</keyword>
	<keyword>Thromboembolism</keyword>
	<keyword>Hypersensitivity</keyword>
	<keyword>Tumor lysis syndrome</keyword>
	<keyword>Peripheral neuropathy</keyword>
	<keyword>Ischaemic heart disease</keyword>
	<keyword>Cardiac failure</keyword>
	<keyword>Arrhythmia</keyword>
	<keyword>Renal failure</keyword>
	<keyword>Interstitial lung disease</keyword>
	<keyword>Hepatic disorder</keyword>
	<keyword>Hypothyroidism</keyword>
	<keyword>Gastrointestinal perforation</keyword>
	<keyword>Orthostatic hypotension</keyword>
	<keyword>Convulsion</keyword>
	<keyword>Somnolence</keyword>
	<keyword>Confusion</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Dizziness</keyword>
	<keyword>Blurred vision</keyword>
	<keyword>Second primary cancer</keyword>
	<keyword>Cataract</keyword>
	<keyword>Revlimid capsule</keyword>
</DOC>